Genotype-Tailored ERK/MAPK Pathway and HDAC Inhibition Rewires the Apoptotic Rheostat to Trigger Colorectal Cancer Cell Death.

Saved in:
Bibliographic Details
Title: Genotype-Tailored ERK/MAPK Pathway and HDAC Inhibition Rewires the Apoptotic Rheostat to Trigger Colorectal Cancer Cell Death.
Authors: Jenkins LJ; Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia., Luk IY; Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia., Fairlie WD; Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia.; Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia., Lee EF; Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia.; Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia., Palmieri M; Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia., Schoffer KL; Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia., Tan T; Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia., Ng I; Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia., Vukelic N; Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia., Tran S; Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia., Tse JWT; Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia., Nightingale R; Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia., Alam Z; Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia., Chionh F; Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia., Iatropoulos G; Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia., Ernst M; Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia., Afshar-Sterle S; Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia., Desai J; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Gibbs P; Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia., Sieber OM; Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.; Department of Medical Biology, The University of Melbourne, Melbourne, Victoria, Australia.; Department of Surgery, The University of Melbourne, Melbourne, Victoria, Australia.; Department of Biochemistry and Molecular Biology, Monash University, Melbourne, Victoria, Australia., Dhillon AS; Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.; The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Deakin University, Geelong, Australia., Tebbutt NC; Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia.; Department of Surgery, The University of Melbourne, Melbourne, Victoria, Australia., Mariadason JM; Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia.
Source: Molecular cancer therapeutics [Mol Cancer Ther] 2023 Jan 03; Vol. 22 (1), pp. 52-62.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1538-8514
DOI:10.1158/1535-7163.MCT-22-0101